Patient Perceptions and Potential Utility of Pharmacogenetic Testing in Chronic Pain Management and Opioid Use Disorder in the Camden Opioid Research Initiative

Dara Kusic; Jessica Heil; Stefan Zajic; Andrew Brangan; Oluseun Dairo; Gretchen Smith; Diego Morales-Scheihing; Russell J. Buono; Thomas N. Ferraro; Rachel Haroz; Matthew Salzman; Kaitlan Baston; Elliot Bodofsky; Michael Sabia; Alissa Resch; Laura B. Scheinfeldt

doi:10.3390/pharmaceutics14091863

Patient Perceptions and Potential Utility of Pharmacogenetic Testing in Chronic Pain Management and Opioid Use Disorder in the Camden Opioid Research Initiative

Dara Kusic, Jessica Heil, Stefan Zajic, Andrew Brangan, Oluseun Dairo, Gretchen Smith, Diego Morales-Scheihing, Russell J. Buono, Thomas N. Ferraro, Rachel Haroz, Matthew Salzman, Kaitlan Baston, Elliot Bodofsky, Michael Sabia, Alissa Resch, Laura B. Scheinfeldt

CMSRU Biomedical Science

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Pharmacogenetics (PGx) has the potential to improve opioid medication management. Here, we present patient perception data, pharmacogenetic data and medication management trends in patients with chronic pain (arm 1) and opioid use disorder (arm 2) treated at Cooper University Health Care in Camden City, NJ. Our results demonstrate that the majority of patients in both arms of the study (55% and 65%, respectively) are open to pharmacogenetic testing, and most (66% and 69%, respectively) believe that genetic testing has the potential to improve their medical care. Our results further support the potential for CYP2D6 PGx testing to inform chronic pain medication management for poor metabolizers (PMs) and ultrarapid metabolizers (UMs). Future efforts to implement PGx testing in chronic pain management, however, must address patient concerns about genetic test result access and genetic discrimination.

Original language	English (US)
Article number	1863
Journal	Pharmaceutics
Volume	14
Issue number	9
DOIs	https://doi.org/10.3390/pharmaceutics14091863
State	Published - Sep 2022

All Science Journal Classification (ASJC) codes

Pharmaceutical Science

Access to Document

10.3390/pharmaceutics14091863

Cite this

Kusic, D., Heil, J., Zajic, S., Brangan, A., Dairo, O., Smith, G., Morales-Scheihing, D., Buono, R. J., Ferraro, T. N., Haroz, R., Salzman, M., Baston, K., Bodofsky, E., Sabia, M., Resch, A., & Scheinfeldt, L. B. (2022). Patient Perceptions and Potential Utility of Pharmacogenetic Testing in Chronic Pain Management and Opioid Use Disorder in the Camden Opioid Research Initiative. Pharmaceutics, 14(9), Article 1863. https://doi.org/10.3390/pharmaceutics14091863

@article{f96b4e12df6c42f1b12a418633eb18fd,

title = "Patient Perceptions and Potential Utility of Pharmacogenetic Testing in Chronic Pain Management and Opioid Use Disorder in the Camden Opioid Research Initiative",

abstract = "Pharmacogenetics (PGx) has the potential to improve opioid medication management. Here, we present patient perception data, pharmacogenetic data and medication management trends in patients with chronic pain (arm 1) and opioid use disorder (arm 2) treated at Cooper University Health Care in Camden City, NJ. Our results demonstrate that the majority of patients in both arms of the study (55% and 65%, respectively) are open to pharmacogenetic testing, and most (66% and 69%, respectively) believe that genetic testing has the potential to improve their medical care. Our results further support the potential for CYP2D6 PGx testing to inform chronic pain medication management for poor metabolizers (PMs) and ultrarapid metabolizers (UMs). Future efforts to implement PGx testing in chronic pain management, however, must address patient concerns about genetic test result access and genetic discrimination.",

author = "Dara Kusic and Jessica Heil and Stefan Zajic and Andrew Brangan and Oluseun Dairo and Gretchen Smith and Diego Morales-Scheihing and Buono, {Russell J.} and Ferraro, {Thomas N.} and Rachel Haroz and Matthew Salzman and Kaitlan Baston and Elliot Bodofsky and Michael Sabia and Alissa Resch and Scheinfeldt, {Laura B.}",

note = "Funding Information: This work was supported by the State of New Jersey. Publisher Copyright: {\textcopyright} 2022 by the authors.",

year = "2022",

month = sep,

doi = "10.3390/pharmaceutics14091863",

language = "English (US)",

volume = "14",

journal = "Pharmaceutics",

issn = "1999-4923",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "9",

}

Kusic, D, Heil, J, Zajic, S, Brangan, A, Dairo, O, Smith, G, Morales-Scheihing, D, Buono, RJ, Ferraro, TN, Haroz, R, Salzman, M, Baston, K, Bodofsky, E, Sabia, M, Resch, A & Scheinfeldt, LB 2022, 'Patient Perceptions and Potential Utility of Pharmacogenetic Testing in Chronic Pain Management and Opioid Use Disorder in the Camden Opioid Research Initiative', Pharmaceutics, vol. 14, no. 9, 1863. https://doi.org/10.3390/pharmaceutics14091863

TY - JOUR

T1 - Patient Perceptions and Potential Utility of Pharmacogenetic Testing in Chronic Pain Management and Opioid Use Disorder in the Camden Opioid Research Initiative

AU - Kusic, Dara

AU - Heil, Jessica

AU - Zajic, Stefan

AU - Brangan, Andrew

AU - Dairo, Oluseun

AU - Smith, Gretchen

AU - Morales-Scheihing, Diego

AU - Buono, Russell J.

AU - Ferraro, Thomas N.

AU - Haroz, Rachel

AU - Salzman, Matthew

AU - Baston, Kaitlan

AU - Bodofsky, Elliot

AU - Sabia, Michael

AU - Resch, Alissa

AU - Scheinfeldt, Laura B.

PY - 2022/9

Y1 - 2022/9

N2 - Pharmacogenetics (PGx) has the potential to improve opioid medication management. Here, we present patient perception data, pharmacogenetic data and medication management trends in patients with chronic pain (arm 1) and opioid use disorder (arm 2) treated at Cooper University Health Care in Camden City, NJ. Our results demonstrate that the majority of patients in both arms of the study (55% and 65%, respectively) are open to pharmacogenetic testing, and most (66% and 69%, respectively) believe that genetic testing has the potential to improve their medical care. Our results further support the potential for CYP2D6 PGx testing to inform chronic pain medication management for poor metabolizers (PMs) and ultrarapid metabolizers (UMs). Future efforts to implement PGx testing in chronic pain management, however, must address patient concerns about genetic test result access and genetic discrimination.

AB - Pharmacogenetics (PGx) has the potential to improve opioid medication management. Here, we present patient perception data, pharmacogenetic data and medication management trends in patients with chronic pain (arm 1) and opioid use disorder (arm 2) treated at Cooper University Health Care in Camden City, NJ. Our results demonstrate that the majority of patients in both arms of the study (55% and 65%, respectively) are open to pharmacogenetic testing, and most (66% and 69%, respectively) believe that genetic testing has the potential to improve their medical care. Our results further support the potential for CYP2D6 PGx testing to inform chronic pain medication management for poor metabolizers (PMs) and ultrarapid metabolizers (UMs). Future efforts to implement PGx testing in chronic pain management, however, must address patient concerns about genetic test result access and genetic discrimination.

UR - http://www.scopus.com/inward/record.url?scp=85138680811&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85138680811&partnerID=8YFLogxK

U2 - 10.3390/pharmaceutics14091863

DO - 10.3390/pharmaceutics14091863

M3 - Article

AN - SCOPUS:85138680811

SN - 1999-4923

VL - 14

JO - Pharmaceutics

JF - Pharmaceutics

IS - 9

M1 - 1863

ER -

Patient Perceptions and Potential Utility of Pharmacogenetic Testing in Chronic Pain Management and Opioid Use Disorder in the Camden Opioid Research Initiative

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this